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Abstract 
Introduction: It has not been established whether CHEK2 and NOD2 variants are present in Latvia and whether
inherited variation in these genes influences cancer risk in this population. 
Aim of the study: To evaluate the role of CHEK2 and NOD2 mutations in breast and colorectal cancers in the
population of Latvia. 
Materials and methods: Peripheral venous blood samples were collected from 185 breast cancer and 235
colorectal cancer consecutive hospital-based cases from 11/2003 to 06/2005. The population control group
included blood samples from the clamped distal part of the  umbilical cord from 978 consecutive anonymous
newborns born between 03/2005 and 08/2005. All cases and controls were tested for the presence of NOD2
3020insC mutation and CHEK2 I157T mutation. 
Results: NOD2 3020insC was present in 7.7% (18/235) of CRC cancers, in 9.2% (17/185) of breast cancers
and in 7.7% (75/974) of controls. CHEK2 I157T variant was found in 7.6% (14/185) of breast cancer cases,
10.2% (24/235) of colon cancer cases and in 6.4% (63/978) of population controls. NOD2 3020insC variant
was associated with increased risk of breast cancer (OR=2.5, p<0.05) for cases diagnosed at age between
51 and 60 years. CHEK2 I157T variant was associated with increased risk of colorectal cancer (OR=1.7,
p<0.05) with the highest OR=2.0 for cases diagnosed at age >70 yrs.
Conclusions: NOD2 3020insC and CHEK2 I157T variants may be associated with increased risk of colorectal
and breast cancers in Latvia. 
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Introduction
There is continuing interest in identifying DNA
variants which are associated with an increased risk of
cancer. Several studies have suggested an increased
risk of cancer in individuals who carry a mutation in
the CHEK2 gene, one of the genes in the DNA
damage signalling pathway. Originally, a single founder
allele in CHEK2, 1100delC, was reported to be a low-
penetrance breast cancer susceptibility allele in several
studies, and in many ethnic groups [1-4]. Then, a
positive association was found between CHEK2 variants
and prostate cancer in the USA, Finland and Poland
[5-7]. Recently, it was reported that individuals with a
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single common founder allele in Poland (the I157T
missense variant) have increased risk of cancer
development in many organs including the breast,
prostate, thyroid, kidney and colon [8].
The NOD2 gene is associated with susceptibility to
inflammatory bowel disease – Crohn’s disease [9]. It
was reported that a single truncating mutation in
NOD2, 3020insC, may confer increased risk of late
onset colorectal cancer [10] and then that a NOD2
mutation may be associated with increased
susceptibility to lung, ovarian, early-onset laryngeal
cancer and early onset breast cancer [11].
It has not been established whether CHEK2 and
NOD2 variants are present in Latvia and whether
inherited variation in these genes influences cancer risk
in this population. To address these issues, we report here
the results of the CHEK2 and NOD2 analyses for 185
breast cancer cases and 235 colorectal cancer cases. 
Methods
From 11/2003 to 06/2005 family cancer history
and peripheral venous blood samples were collected
in 185 consecutive hospital-based breast cancer cases
and 235 colorectal cancer cases. The population
control group included umbilical cord blood samples
from 978 consecutively collected anonymous newborn
children between 03/2005 and 08/2005. Cases were
considered consecutive if at least 70% of newly
diagnosed patients were involved in the study from a
particular hospital and department in a given period
of time. In the breast cancer group, 82 cases were
involved from the Regional Oncology Hospital of
Daugavpils, 72 cases from the Regional Oncology
Hospital of Liepaja and 31 cases from Paula Stradins
University Hospital. 
In the CRC group, 92 cases were involved from the
Oncology Center of Latvia, 73 cases from Paula
Stradins University Hospital, 46 cases from the Regional
Oncology Hospital of Liepaja and 24 cases from the
Regional Oncology Hospital of Daugavpils. In the CRC
group 114/235 (49%) were females and 121/235
(51%) were males. The distribution of breast and
colorectal cancers according to the age of diagnosis
are summarized in Table 1.
Median age of CRC onset was 66 years and
median onset of breast cancer was 60 years.
In order to evaluate the representativity of breast
cancer and CRC groups, they were compared to all
newly diagnosed breast and colorectal cancers
diagnosed between years 1999 and 2003 in Latvia
and it was concluded that breast and CRC groups are
comparable to the total group of newly diagnosed
breast cancers and CRCs as far as age at time of
diagnosis and gender are concerned.
All cancer and control group samples were tested
for the presence of NOD2 3020insC and CHEK2
I157T polymorphisms as described by G. Kurzawski
and C. Cybulski respectively [7-10]. 
The study was approved by the Ethics Committee
of the Pauls Stradins University Hospital and the Central
Committee of Medical Ethics.
Table 1. Distribution of breast cancer and CRC group according to age at time of cancer diagnosis
Decade Breast cancer % CRC %
20-29 1 0.60% 2 0.90%
30-39 9 4.90% 4 1.70%
40-49 31 16.90% 14 6.00%
subtotal (<50) 41 22.40% 20 8.60%
50-59 46 25.10% 37 15.70%
60-69 55 30.00% 79 33.60%
70-79 30 16.40% 80 34.00%
80-89 10 5.50% 17 7.20%
>90 1 0.55% 2 0.85%
subtotal (>50) 142 77.60% 215 91.40%
total 183* 235
*In 2 cases time of breast cancer onset was unknown
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All patients completed a family cancer history
questionnaire. Family cancer histories were analysed
according to internationally approved clinical
diagnostic hereditary cancer criteria. If there were no
malignancies among relatives of the proband the
patient was classified as being negative for a family
history of the disease.
The prevalence of the CHEK2 and NOD2 alleles
in cases and population controls was compared. Odds
ratios were generated from two-by-two tables and
statistical significance was assessed using the Fisher
exact test. The odds ratios were used as estimates of
relative risk.
Results
The NOD2 3020insC mutation was present in
7.7% (18/235) of CRC cancers, in 9.2% (17/185) of
breast cancer patients and in 7.7% (75/974) of the
control group. The CHEK2 I157T polymorphism was
found in 7.6% (14/185) of breast cancer patients,
10.2% (24/235) of colon cancer cases and in 6.4%
(63/978) of the control group.  
Statistically significant differences compared to
population controls were observed: for NOD2
3020insC for the subgroup of breast cancer patients
diagnosed at the age between 51 and 60 (OR=2.5,
p<0.05) (Table 2); for CHEK2 I157T for the entire series
of consecutive colorectal cancers (OR=1.7, p<0.05).
The highest odds ratio (OR=2.0, p=0.06) was
observed for CRC diagnosed at age >70 yrs (Table 3).
In seven NOD2 3020insC positive cases family
cancer history was negative. In another 10 cases there
were two other relatives affected with cancer in their
families, which did not match any recognised
diagnostic criteria of hereditary cancer. A single NOD2
3020insC positive patient had a family history of three
CRCs in their family. 
The average age of cancer onset for breast cancer
patients harbouring NOD2 3020insC was 58 years.
In six NOD2 3020insC positive breast cancer patients
their family cancer history was negative. In 5/17 (29%)
cases at least two breast cancers were identified in
these families and one family matched the criteria of
belonging to unspecified strong cancer family
aggregation (CFA).
The average age of disease onset for CHEK2 I157T
positive CRC cases was 67. In 16 cases with the I157T
mutation family cancer history was negative. Among
another 8 CHEK2 I157T positive CRC patients, 3/24
(13%) matched criteria of CFA, 1/24 (4%) case was
suspected of hereditary non-polyposis colorectal cancer
(HNPCC) and 1/24 (4%) case had late-onset HNPCC.
The average age of breast cancer onset for CHEK2
I157T positive cases was 59 years. In four CHEK2
I157T positive breast cancer cases family cancer history
was negative. 8/14 (57%) cases had familial breast
cancer.
Discussion and conclusions
This first study of low penetrant CRC and breast
cancer predisposition markers in Latvia shows a trend
that both NOD2 3020insC and CHEK2 I157T
polymorphisms are associated with increased risk of
colorectal and breast cancers. 
Statistically significant differences between cases
and controls were not as well expressed as it has been
recognised in earlier studies from Poland, probably
because of the much smaller number of cases and
controls, but the general trend was the same – NOD2
3020insC was more frequent among early onset breast
cancers and late onset CRCs; CHEK2 I157T was in
excess among colorectal cancer and late onset breast
cancer cases. In our study we focused on breast and
Table 2. Prevalence of NOD2 3020insC mutation in breast cancer
patients, according to age at onset   
Age groups Prevalence of NOD2 3020insC
<41 0% (0/10)
41-50 9.7% (3/31)
51-60 17%  (8/46)*
61-70 7.3% (4/55)
>70 4.9% (2/41)
total  9.1% (17/185)
* - statistically significant difference as compared to population controls 
(7.7% (75/974); OR=2.5, p<0.05)
Table 3. Prevalence of CHEK2 I157T mutation in colorectal cancer
cases according to age at onset 






* - significant difference compared to controls (6.4% (63/978); 
OR=1.7, p<0.05)
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colon cancers. Since for both sites we saw a similar
trend as described earlier by the Polish group, we
expect that the spectrum of tumours associated with
mutations in NOD2 and CHEK2 in Latvia will also
include other cancers. However, further studies on
larger series of cancers and of different sites are
necessary in this regard.
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